LHRH agonists are the mainstay in the therapy of prostate cancer and act through the down-regulation of LHRH-R.[23] Moreover, our previous studies showed that the LHRH antagonist, cetrorelix[24], and the cytotoxic analog, AN-152[25] can be successfully used for the treatment of cancers of the reproductive system[25] and of other organs.[1, 2, 26-28]. The gene discussed is GNRH1; the disease is reproductive system cancer.